Immunocore Holdings (IMCR) Net Margin (2021 - 2026)
Immunocore Holdings (IMCR) posted Net Margin of 12.16% for Q1 2026, up 142.26% sequentially from 28.77% in Q4 2025, and up 685.0% YoY from 1.55% in Q1 2025.
Powered by 
Analysis
Immunocore Holdings (IMCR) Net Margin (2021 - 2026) Analysis & Trends
Immunocore Holdings has reported Net Margin for 6 years, with the latest figure at 12.16% in Q1 2026.
- Quarterly Net Margin rose 685.0% year-over-year to 12.16% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6.68% (down 18.0% YoY) and the FY2025 annual result came in at 8.88%, up 759.0% from the prior year.
- Net Margin climbed to 12.16% in Q1 2026 per IMCR's latest filing, from 28.77% in the prior quarter.
- Over five years, Net Margin peaked at 15.12% in Q3 2022 and troughed at 52.99% in Q4 2022.
- A 5-year average of 16.75% and a median of 21.77% in 2023 frame the typical range for Net Margin.
- The sharpest annual moves came in 2022 and 2023: Net Margin soared 54445 bps in 2022, then plunged 1372 bps in 2023.
- Over 5 years, Net Margin stood at 52.99% in 2022, then jumped by 47 bps to 28.12% in 2023, then retreated by 1 bps to 28.28% in 2024, then decreased by 2 bps to 28.77% in 2025, then surged by 142 bps to 12.16% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 12.16%, 28.77%, and 0.19% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Immunocore Holdings | 1.85 Bn | 965.54 Mn | 114.84 Mn | -0.70% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.70% |
| Mar 31, 2026 | 12.16% |
| Dec 31, 2025 | -28.77% |
| Sep 30, 2025 | -0.19% |
| Jun 30, 2025 | -10.51% |
| Mar 31, 2025 | 5.31% |
| Dec 31, 2024 | -28.28% |
| Sep 30, 2024 | 10.89% |
| Jun 30, 2024 | -15.42% |
| Mar 31, 2024 | -34.72% |
| Dec 31, 2023 | -28.12% |
| Sep 30, 2023 | 1.40% |
| Jun 30, 2023 | -29.48% |
| Mar 31, 2023 | -35.60% |
| Dec 31, 2022 | -52.44% |
| Sep 30, 2022 | 15.12% |
| Jun 30, 2022 | -48.85% |
| Dec 31, 2021 | -597.44% |
| Sep 30, 2021 | -508.68% |